Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

Publication ,  Journal Article
Tyring, S; Gottlieb, A; Papp, K; Gordon, K; Leonardi, C; Wang, A; Lalla, D; Woolley, M; Jahreis, A; Zitnik, R; Cella, D; Krishnan, R
Published in: Lancet
January 7, 2006

BACKGROUND: Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated with the condition. METHODS: 618 patients with moderate to severe psoriasis received double-blind treatment with placebo or 50 mg twice-weekly etanercept. The primary efficacy endpoint was a 75% or greater improvement from baseline in psoriasis area and severity index score (PASI 75) at week 12. Secondary and other endpoints included the functional assessment of chronic illness therapy fatigue (FACIT-F) scale, the Hamilton rating scale for depression (Ham-D), the Beck depression inventory (BDI), and adverse events. Efficacy analyses were based on the allocated treatment. Analyses and summaries of safety data were based on the actual treatment received. This study is registered with with the identifier NCT00111449. FINDINGS: 47% (147 of 311) of patients achieved PASI 75 at week 12, compared with 5% (15 of 306) of those receiving placebo (p<0.0001; difference 42%, 95% CI 36-48). Greater proportions of patients receiving etanercept had at least a 50% improvement in Ham-D or BDI at week 12 compared with the placebo group; patients treated with etanercept also had significant and clinically meaningful improvements in fatigue (mean FACIT-F improvement 5.0 vs 1.9; p<0.0001, difference 3.0, 95% CI 1.6-4.5). Improvements in fatigue were correlated with decreasing joint pain, whereas improvements in symptoms of depression were less correlated with objective measures of skin clearance or joint pain. INTERPRETATION: Etanercept treatment might relieve fatigue and symptoms of depression associated with this chronic disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

January 7, 2006

Volume

367

Issue

9504

Start / End Page

29 / 35

Location

England

Related Subject Headings

  • Severity of Illness Index
  • Receptors, Tumor Necrosis Factor
  • Psoriasis
  • Middle Aged
  • Male
  • Immunoglobulin G
  • Humans
  • General & Internal Medicine
  • Female
  • Fatigue
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., … Krishnan, R. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet, 367(9504), 29–35. https://doi.org/10.1016/S0140-6736(05)67763-X
Tyring, Stephen, Alice Gottlieb, Kim Papp, Ken Gordon, Craig Leonardi, Andrea Wang, Deepa Lalla, et al. “Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.Lancet 367, no. 9504 (January 7, 2006): 29–35. https://doi.org/10.1016/S0140-6736(05)67763-X.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006 Jan 7;367(9504):29–35.
Tyring, Stephen, et al. “Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.Lancet, vol. 367, no. 9504, Jan. 2006, pp. 29–35. Pubmed, doi:10.1016/S0140-6736(05)67763-X.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006 Jan 7;367(9504):29–35.
Journal cover image

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

January 7, 2006

Volume

367

Issue

9504

Start / End Page

29 / 35

Location

England

Related Subject Headings

  • Severity of Illness Index
  • Receptors, Tumor Necrosis Factor
  • Psoriasis
  • Middle Aged
  • Male
  • Immunoglobulin G
  • Humans
  • General & Internal Medicine
  • Female
  • Fatigue